Literature DB >> 1975510

Allelotype of human malignant astrocytoma.

D Fults1, C A Pedone, G A Thomas, R White.   

Abstract

Astrocytoma, the most common brain tumor in humans, is usually malignant and virtually incurable. Two types of malignant astrocytomas can be distinguished histopathologically: anaplastic astrocytoma and glioblastoma multiforme. Studies using DNA markers that detect restriction fragment length polymorphisms have shown that loci on chromosomes 10 and 17p are lost frequently in tumor DNA from malignant astrocytoma patients, suggesting that tumor suppressor genes important in astrocytoma tumorigenesis may be present on 2 different chromosomes. To identify additional regions of chromosome loss, we carried out an allelotype analysis of 41 malignant astrocytoma patients using restriction fragment length polymorphism markers for each arm of every human autosome. Loss of heterozygosity was found for every autosome except chromosome 21, indicating an even greater complexity of genomic alterations than reported previously. Many tumors showed loss of heterozygosity for multiple chromosomes and the number of chromosomes involved correlated with tumor histopathology. A high-resolution restriction fragment length polymorphism study of chromosome 10 loci in these patients showed that loss of broad regions of chromosome 10 was a common event, particularly in glioblastoma multiforme. An allelotype analysis has been carried out on only one other tumor, human colorectal carcinoma. Different profiles of allele loss were observed in malignant astrocytoma and colorectal carcinoma, suggesting that the genetic events leading to these 2 human cancers may proceed along different pathways.

Entities:  

Mesh:

Year:  1990        PMID: 1975510

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  28 in total

1.  Alleletyping of an oligodendrocyte-type-2 astrocyte lineage derive from a human glioblastoma multiforme.

Authors:  X Mao; R Barfoot; R A Hamoudi; M Noble
Journal:  J Neurooncol       Date:  1998-12       Impact factor: 4.130

Review 2.  Molecular genetics of neurological tumours.

Authors:  R Y Chung; B R Seizinger
Journal:  J Med Genet       Date:  1992-06       Impact factor: 6.318

3.  P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase.

Authors:  M P Myers; J P Stolarov; C Eng; J Li; S I Wang; M H Wigler; R Parsons; N K Tonks
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-19       Impact factor: 11.205

4.  p53 protein in pediatric malignant astrocytomas: a study of 21 patients.

Authors:  M B Bhattacharjee; J M Bruner
Journal:  J Neurooncol       Date:  1997-05       Impact factor: 4.130

5.  Loss of heterozygosity for DNA polymorphisms mapping to chromosomes 10 and 17 and prognosis in patients with gliomas.

Authors:  C E Jones; M B Davis; J L Darling; J F Geddes; D G Thomas; A E Harding
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-02       Impact factor: 10.154

6.  Negative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells. Implication of the tumor suppressor genes for gene therapy.

Authors:  A Asai; Y Miyagi; A Sugiyama; M Gamanuma; S H Hong; S Takamoto; K Nomura; M Matsutani; K Takakura; Y Kuchino
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Patterns of epidermal growth factor receptor amplification in malignant gliomas.

Authors:  G Sauter; T Maeda; F M Waldman; R L Davis; B G Feuerstein
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

Review 8.  Genetic alterations in glioma and medulloblastoma.

Authors:  B K Rasheed; S H Bigner
Journal:  Cancer Metastasis Rev       Date:  1991-12       Impact factor: 9.264

9.  p53 protein expression in central nervous system tumors: an immunohistochemical study with CM1 polyvalent and DO-7 monoclonal antibodies.

Authors:  E Karamitopoulou; E Perentes; I Diamantis
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

10.  Aggressive oligodendroglioma predicted by chromosome 10 restriction fragment length polymorphism analysis. Case study.

Authors:  J K Wu; R D Folkerth; Z Ye; B T Darras
Journal:  J Neurooncol       Date:  1993-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.